How do kidney function and electrolyte balance affect digoxin dosing and toxicity risk?

How do kidney function and electrolyte balance affect digoxin dosing and toxicity risk?

• A. Kidneys clear digoxin; electrolyte disturbances (hypokalemia, hypomagnesemia) increase toxicity risk; adjust dose with renal function.
• B. Hepatic clearance and potassium do not affect digoxin toxicity.
• C. Potassium levels alone determine digoxin dose.
• D. Renal function is not considered when dosing digoxin.

Answer: (A)

The main idea is that digoxin dosing hinges on kidney function and electrolyte balance because these factors directly influence how much of the drug stays in the body and how strongly it can affect the heart. Digoxin is cleared by the kidneys, so reduced renal function leads to higher serum levels for the same dose, increasing the risk of toxicity. That’s why dosing must be adjusted based on renal function—often by lowering the dose or extending the interval between doses as kidney performance declines. Electrolyte disturbances, particularly low potassium and low magnesium, further raise toxicity risk. When potassium or magnesium are deficient, digoxin binds more readily to the Na+/K+-ATPase pump in cardiac cells, amplifying its effects on conduction and increasing the likelihood of dangerous arrhythmias. This potentiation is a key reason to correct electrolyte abnormalities while adjusting the digoxin dose. So, the correct concept is that kidneys clear digoxin and electrolyte imbalances raise toxicity risk, with dose adjustments made according to renal function to prevent accumulation and adverse effects. The other statements aren’t accurate because hepatic clearance plays little role with digoxin, potassium levels alone do not determine the dose, and renal function is indeed a critical consideration when dosing.

The main idea is that digoxin dosing hinges on kidney function and electrolyte balance because these factors directly influence how much of the drug stays in the body and how strongly it can affect the heart. Digoxin is cleared by the kidneys, so reduced renal function leads to higher serum levels for the same dose, increasing the risk of toxicity. That’s why dosing must be adjusted based on renal function—often by lowering the dose or extending the interval between doses as kidney performance declines.

Electrolyte disturbances, particularly low potassium and low magnesium, further raise toxicity risk. When potassium or magnesium are deficient, digoxin binds more readily to the Na+/K+-ATPase pump in cardiac cells, amplifying its effects on conduction and increasing the likelihood of dangerous arrhythmias. This potentiation is a key reason to correct electrolyte abnormalities while adjusting the digoxin dose.

So, the correct concept is that kidneys clear digoxin and electrolyte imbalances raise toxicity risk, with dose adjustments made according to renal function to prevent accumulation and adverse effects.

The other statements aren’t accurate because hepatic clearance plays little role with digoxin, potassium levels alone do not determine the dose, and renal function is indeed a critical consideration when dosing.